Donata Ponikwicka‐Tyszko

ORCID: 0000-0003-1086-7460 · 7 papers in corpus
2025
Molecular medicine (Cambridge, Mass.) ·doi:10.1186/s10020-025-01292-5

BACKGROUND: Extragonadal follicle-stimulating hormone (FSH) receptor (FSHR) expression in various cancers and their endothelial vessel cells has highlighted novel opportunities for targeted FSHR therapy. METHODS: We investigated the specifi…

2024
Molecular medicine (Cambridge, Mass.) ·doi:10.1186/s10020-024-01015-2

BackgroundExtragonadal follicle-stimulating hormone receptor (FSHR) expression at low levels has been shown in several normal and tumor tissues, including myometrium and adipose tissue. FSH-FSHR signaling in the myometrium has been suggeste…

article 2022
Journal of clinical medicine ·doi:10.3390/jcm11154407

Adenomyosis is a common gynaecological disease associated with the presence of endometrial lesions in the uterine myometrium. Estrogens have been proven to be the crucial hormones driving the growth of adenomyosis. Little is known about the…

2021
Journal of clinical medicine ·doi:10.3390/jcm10245945

Bisphenol A (BPA), the most common endocrine-disrupting chemical, has been associated with male reproductive dysfunctions. Recently, it has been shown that BPA may also affect miRNAs expression. Herein, we aimed to evaluate the association …

2019
Frontiers in endocrinology ·doi:10.3389/fendo.2019.00032

Expression of the follicle-stimulating hormone receptor (FSHR), besides gonadal tissues, has recently been detected in several extragonadal normal and tumorous tissues, including different types of primary and metastatic cancer and tumor ve…

article 2016
The Journal of clinical endocrinology and metabolism ·doi:10.1210/jc.2016-1014

CONTEXT: FSH receptor (FSHR), besides being expressed in gonads, is also expressed in some extragonadal tissues at low levels. OBJECTIVE: We examined the functional expression of FSHR in different types of endometriotic lesions. DESIGN: Ext…

2016
Scientific reports ·doi:10.1038/srep37095

Expression of follicle-stimulation hormone receptor (FSHR) is confined to gonads and at low levels to some extragonadal tissues like human umbilical vein endothelial cells (HUVEC). FSH-FSHR signaling was shown to promote HUVEC angiogenesis …